Targeted albumin spherical nucleic acid medicine as well as preparation method and use method thereof
Through the design of albumin spherical nucleic acid drugs, hydrophobic interactions are used to form a targeted structure, and the hydrophobic drugs and nucleic acid aptamers are specifically delivered to the tumor site, solving the problems of insufficient targeting and stability in the prior art, significantly improving the The effect of tumor treatment.
Patent Information
- Application Number
- CN202411068030.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing tumor treatment drugs have insufficient targeting and stability, resulting in strong toxicity and high side reactions, making it difficult to effectively target the tumor site, especially in the treatment of deep or large tumors such as pancreatic cancer. good.
Using albumin spherical nucleic acid drugs, targeted delivery is achieved by encapsulating the hydrophobic drug inside the albumin and using the hydrophobic interaction of multiple hydrophobic domains with the nucleic acid aptamer. The drug includes hydrophobic molecules wrapped inside albumin such as paclitaxel, illistolimu and near-infrared photothermal agent IR1061, which modify multiple nucleic acid aptamers on the surface and specifically target tumor cells or mitochondria.
Improve the targeting and stability of the drug, achieve efficient delivery of a variety of hydrophobic drugs, and significantly improve the tumor treatment effect, especially in mild photothermal treatment and copper death treatment for pancreatic cancer and large tumors. Targeting ability and therapeutic effect.
Smart Images

Figure CN118986929A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of tumor drug research and development, and in particular to the research and development of albumin-targeted drugs related to clinical tumor treatment. Background Art
[0002] Human serum albumin (HSA), as one of the main components of serum proteins, has rich functional groups and natural amphiphilic structures, and can be covalently or non-covalently linked to drug molecules. In addition, it has the advantages of wide sources, low cost, long half-life, and good biocompatibility, and is widely used in drug carrier research. For example, albumin-bound paclitaxel (Abraxane) has been approved by the FDA for the late-stage clinical treatment of multiple tumors. However, existing albumin delivery drugs rely solely on the enhanced permeability and retention effect (EPR) of solid tumors to target drugs to the tumor site and protect normal tissues or cells from damage, resulting in strong drug toxicity and large side effects, limiting its further clinical application.
[0003] Aptamer is a functional oligonucleotide sequence that can specifically recognize targets such as proteins, cells, bacteria, and viruses. It can not only be used directly as a protein blocker, but can also be coupled with small molecule drugs, nanoparticles, or cells for targeted delivery. However, monovalent aptamers have problems such as poor stability, weak affinity, and easy off-target effects, which limit their clinical application in nano-drug delivery.
[0004] Current cancer treatment drugs have some limitations: for example, tumor photothermal therapy is a non-invasive treatment method that induces cell apoptosis and necrosis through local laser thermotherapy, and its clinical application is hindered by both physical and physiological barriers. From the perspective of physical barriers, as the key to photothermal conversion in photothermal therapy, conventional photothermal agents are difficult to effectively achieve active tumor targeting. At the same time, the penetration depth of near-infrared lasers is limited and the temporal and spatial resolution is low, making it impossible to completely ablate large tumors or deep tumors. From the perspective of physiological barriers, the local high temperature (50°C) generated by photothermal therapy can cause severe inflammatory reactions in the body and irreversible damage to surrounding organs. However, due to the thermal damage repair effect of intracellular heat shock proteins, mild photothermal (below 43°C) will significantly inhibit the therapeutic effect of tumors.
[0005] For example, pancreatic cancer is a highly invasive malignant tumor of the digestive system and is known as the "king of cancer." Since pancreatic cancer has an insidious onset and progresses rapidly, most patients are already in the middle or advanced stages when they seek medical treatment. Traditional treatment options are limited and the prognosis is poor. Copper is an essential trace element in living systems and its levels are strictly regulated in the human body. Recently, a new form of cell death related to copper ions, cuprotosis, has been discovered. It relies on copper ion carriers to transport copper into cancer cells, leading to cell death. However, existing copper ion carriers are small molecules with a short blood half-life, making it difficult to transport enough copper to cancer cells. Elesclomol (ES), as a copper ion carrier, can bind Cu 2+ To induce copper cell death in tumor cells, however, existing medical technologies cannot achieve efficient induction of copper death in pancreatic cancer. Summary of the invention
[0006] In view of the shortcomings of existing tumor treatment drugs, the present invention provides a targeted albumin spherical nucleic acid drug, in order to achieve specific targeted delivery for different types of tumors, improve drug treatment effects, and reduce toxic side effects. The drug of the present invention is characterized in that the interior of albumin (HSA) encapsulates hydrophobic molecules, and at the same time, albumin with multiple hydrophobic domains on the surface and multiple nucleic acid aptamer sequences (Apt) with hydrophobic groups at the 5' end are non-covalently modified and bound to each other through hydrophobic interactions to form a spherical nucleic acid structure, and the nucleic acid aptamer has specific targeting.
[0007] Preferably, the hydrophobic molecules include one or more of paclitaxel (PTX), elisemol (ES), Ce6, IR1061 and resveratrol (Res). It is understandable that for those skilled in the art, all hydrophobic drugs that can be delivered by albumin as a carrier in the prior art are included in the connotation of "hydrophobic molecules" of "hydrophobic molecules encapsulated inside albumin (HSA)" defined in the present invention.
[0008] Particularly preferably, the aptamer sequence specifically targets tumor cells, and the hydrophobic molecules include IR1061 and resveratrol (Res) to form IR / Res@HSA-Apt albumin spherical nucleic acid drugs. It is understandable that for those skilled in the art, except for SYL3C, all nucleic acid aptamers that can target tumor cell-specific molecules in the prior art are within the scope of the nucleic acid aptamer selectable in the drug IR / Res@HSA-Apt of the present invention.
[0009] Particularly preferably, the nucleic acid aptamer sequence is SYL3C, which can specifically target the epithelial cell adhesion molecule EpCAM.
[0010] In addition, preferably, the nucleic acid aptamer sequence can also specifically target mitochondria, and the hydrophobic drug is elisemol (ES) to form ES@HSA-Apt albumin spherical nucleic acid drug.
[0011] Preferably, catalase (CAT) is also added to the ES@HSA-Apt conjugate to form an ES@HSA / CAT-Apt albumin spherical nucleic acid drug.
[0012] Particularly preferably, the nucleic acid aptamer sequence specifically targets the cytochrome c molecule (Cyt c) on the surface of mitochondria.
[0013] Particularly preferably, the hydrophobic group at the 5' end of the nucleic acid aptamer sequence is an octadecyl group. Compared with other lipid modifications, the octadecyl nucleic acid aptamer has lower cost and more mature synthesis strategy.
[0014] The present invention also provides a method for preparing a targeted albumin spherical nucleic acid drug, comprising the following steps:
[0015] Step 1: Dissolve the hydrophobic drug;
[0016] Step 2: Take an appropriate volume of albumin solution, slowly add the hydrophobic drug solution to the albumin solution in a predetermined ratio while stirring, and stir for a certain period of time in the dark;
[0017] Step 3: Centrifuge after stirring to remove free molecules;
[0018] Step 4: After centrifugation, the supernatant is dialyzed to obtain the albumin-bound drug (drug@HSA);
[0019] Step 5: Add the aptamer sequence with a hydrophobic group at 5', incubate with constant temperature stirring, and obtain the aptamer-albumin drug conjugate (drug @HSA-Apt)
[0020] The present invention also includes a method for using the targeted albumin spherical nucleic acid drug, that is, using the aforementioned targeted albumin spherical nucleic acid drug for the preparation of drugs related to tumor targeted therapy.
[0021] Beneficial Effects
[0022] 1. Compared with the complex nucleic acid-protein coupling strategy of achieving covalent connection through cross-linking agents, click chemistry and other methods, the present invention adopts the protein spherical nucleic acid (SNA) strategy, introduces octadecyl as a hydrophobic structure into the 5' end of the nucleic acid aptamer, and cleverly utilizes the multiple natural hydrophobic domains on the albumin surface to non-covalently connect multiple nucleic acid aptamers at one time to construct a targeted albumin drug with a spherical nucleic acid structure. Multivalent nucleic acid aptamers are introduced into albumin drugs, and the outer layer is modified with a high-density oligonucleotide layer to construct a spherical nucleic acid delivery platform with albumin nano-drugs as the core, so as to achieve efficient targeted delivery of multiple drugs, thereby being able to specifically deliver various hydrophobic drugs to tumors or other lesion tissues, solving the problems that traditional albumin drugs have poor targeting enrichment and strong systemic side effects that cannot be solved.
[0023] 2. Based on this method, we verified that a variety of hydrophobic drugs (paclitaxel, resveratrol, ilisimol, Ce6, IR1061, etc.) were hydrophobically bound to albumin to form albumin drugs (Drug@HSA), and then coupled with nucleic acid aptamers to form a stable hydrophobic drug delivery system (Drug@HSA-Apt), which showed excellent targeting ability, stability and therapeutic effect beyond expectations in mild photothermal therapy of tumors and copper death therapy.
[0024] In the practice of mild photothermal therapy for tumors, the technical solution of the present invention is the first to precisely target and co-deliver IR1061 and resveratrol based on a targeted albumin drug with a spherical nucleic acid structure for mild photothermal therapy of tumors. Among them, IR1061, as a near-infrared zone II photothermal agent, provides a higher depth of photothermal conversion; resveratrol, as a heat shock protein inhibitor, inhibits thermal damage repair by downregulating heat shock proteins in tumor cells, thereby achieving mild photothermal therapy for targeted tumors.
[0025] In the practice of copper death treatment for pancreatic cancer, the technical solution of the present invention is the first to deliver ilisimol to intracellular mitochondria based on a targeted albumin drug with a spherical nucleic acid structure, thereby sensitizing copper death-induced immunogenic cell death by improving the hypoxic environment.
[0026] 3. Compared with the existing nucleic acid-protein coupling strategy, the one-step modification method of albumin drugs based on hydrophobic interaction has been verified by the present invention. The preparation process is simple, the stability is high, and the versatility is strong. It can conveniently and efficiently transform commercial albumin drugs into targeted drugs with significant therapeutic effects and stable properties, thus solving the pain points of insufficient targeting and insufficient stability in current cancer treatment. At the same time, the manufacturing and synthesis process of the product of this scheme is easy to control quality, overcoming the problems of complex modification and high difficulty of quality control of small nucleic acid drugs, and is expected to realize the industrialization and large-scale production of the targeted albumin spherical nucleic acid drug of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1: (A) Preparation method of targeted albumin spherical nucleic acid drug and its (B) schematic diagram for mild photothermal therapy of tumors and (C) copper-death tumor treatment.
[0028] Figure 2 : Transmission electron microscopy (TEM) images and particle size distribution of targeted albumin spherical nucleic acid drugs loaded with different hydrophobic drugs.
[0029] Figure 3 :Lyophilization-reconstitution characterization and large-scale preparation of albumin-targeted spherical nucleic acid drugs.
[0030] (a) Particle size characterization of PTX@HSA-Apt before and after freeze-drying and reconstitution.
[0031] (b) Gel electrophoresis of PTX@HSA-Apt before and after freeze-drying and reconstitution.
[0032] (c) and (d) are photos of the large-scale preparation of 100 mL PTX@HSA-Apt before and after freeze-drying.
[0033] Figure 4 : IR / Res@HSA-Apt has stable photothermal performance.
[0034] (a) Temperature rise curves of different concentrations of IR / Res@HSA-Apt at 1064 nm.
[0035] (b) The temperature change results of IR / Res@HSA-Apt under 1064nm irradiation for three cycles show that the material has stable photothermal conversion performance.
[0036] Figure 5 : Flow cytometry results showed that the drug IR / Res@HSA-Apt of the present invention can effectively target tumor cells and improve the specific recognition ability of albumin drugs.
[0037] Figure 6 :Lysosomal escape performance of ES@HSA / CAT-Apt.
[0038] Figure 7 :Mitochondrial targeting performance of ES@HSA / CAT-Apt.
[0039] Figure 8 : The targeted albumin spherical nucleic acid drug of the present invention has significant tumor targeting and killing performance.
[0040] (a) Cell proliferation and cytotoxicity (CCK-8 method) showed the comparison of the effects of PBS, IR / Res@HSA-Apt in the absence of light and IR@HSA, Res@HSA, IR / Res@HSA, and IR / Res@HSA-Apt on tumor cell viability under light conditions.
[0041] (b) Flow cytometry detection of cell apoptosis (Annexin V / PI method) showed the comparison of the killing effects of Control, IR@HSA, Res@HSA, IR / Res@HSA, and IR / Res@HSA-Apt on tumor cells under no light and light conditions.
[0042] (c) Cell proliferation and cytotoxicity (CCK-8 method) showed the comparison of the effects of tumor cell viability under the treatment of ES, ES@HSA, ES@HSA / CAT, and ES@HSA / CAT-Apt.
[0043] Fig. 9 : IR@HSA-Apt has excellent targeting performance in vivo.
[0044] (a) In vivo imaging results of 4T1 tumor-bearing mice showed that IR@HSA-Apt still had significant tumor targeting and retention after 36 hours in vivo.
[0045] (b) Fluorescence statistics of the tumor sites at different time points in 4T1 tumor-bearing mice.
[0046] Fig.10 : The thermal imaging results of IR@HSA-Apt in 4T1 tumor-bearing mice showed that the material can achieve mild photothermal conversion in vivo.
[0047] Fig.11 :Experimental results of mild photothermal therapy of tumors using IR / Res@HSA-Apt.
[0048] (a) Tumor growth curve of 4T1 tumor-bearing mice.
[0049] (b) Body weight change curve of 4T1 tumor-bearing mice.
[0050] (c) Fluorescence image of heat shock protein expression in tumor tissue.
[0051] Fig.12 : Copper-death tumor therapy by ES@HSA / CAT-Apt.
[0052] (a) Body weight change curve of Panc02 tumor-bearing mice.
[0053] (b) Tumor growth curve of Panc02 tumor-bearing mice.
[0054] (c) Statistical graph of tumor weight in Panc02 tumor-bearing mice.
[0055] (d) HE sections of tumors in Panc02 tumor-bearing mice after treatment with different drug administration methods. DETAILED DESCRIPTION
[0056] The following is a detailed description of the preparation method, structural characterization, in vitro performance, in vivo targeting, stability, safety and therapeutic effect of the drug involved in the present invention through specific embodiments of the present invention.
[0057] 1. Preparation of albumin-targeted spherical nucleic acid drugs
[0058] Without changing the traditional albumin drug synthesis method, we designed a new albumin drug with active targeting ability. The preparation method of the targeted albumin spherical nucleic acid drug is as described in the following steps:
[0059] (1) Prepare a 40 mg / ml human serum albumin (HSA) solution (ddH2O) and disperse it by ultrasonic for 3 min to completely dissolve the albumin;
[0060] (2) Add hydrophobic drug molecules dissolved in an organic solution, such as paclitaxel (PTX), elisemol (ES), Ce6, IR1061 or resveratrol (Res), to the albumin solution in a certain proportion. Since albumin has a large number of natural hydrophobic domains, under hydrophobic interactions, the nanoparticles formed by albumin aggregation will encapsulate the hydrophobic drugs and form albumin-bound drugs;
[0061] (3) using octadecyl covalently modified at the 5' end of the nucleic acid aptamer (Apt) sequence to introduce a hydrophobic structure into the nucleic acid sequence to form a C18-Apt structure;
[0062] (4) C18-Apt can be non-covalently modified on the surface of albumin nanodrugs through hydrophobic interactions to obtain a stable Drug@HSA-Apt structure.
[0063] The preparation methods of different targeted albumin drugs will be described in detail below.
[0064] 1. Preparation of IR / Res@HSA-Apt
[0065] First, resveratrol (Res) was dissolved in methanol to prepare a 20 mg / mL Res solution, and IR1061 was dissolved in DMSO to prepare a 10 mg / mL IR1061 solution;
[0066] Take an appropriate volume of serum albumin (HSA) solution in a sample bottle and place it on a magnetic stirrer and stir at 800 rpm. While stirring, slowly add Res and IR1061 solution to the HSA solution so that the final ratio of each component in the solution is HSA:IR1061:Res=2:1:3. Stir for 12 hours or more in the dark;
[0067] After stirring, centrifuge at 4000 rpm for 3 min to remove free molecules, and dialyze the supernatant in a dialysis bag (MWCO = 14 kDa) for 24 h to obtain IR / Res@HSA albumin-bound drug;
[0068] Then, C18-SYL3C (SYL3C, a nucleic acid aptamer that specifically targets the epithelial cell adhesion molecule EpCAM) was added until the final concentration of the aptamer was 1 μM. Then, the mixture was incubated on an Eppendorp Thermomixer at 37°C and 300 rpm for 4 h to obtain IR / Res@HSA-Apt, which could be temporarily stored at 4°C for later use.
[0069] 2. Preparation of ES@HSA-Apt
[0070] First, elisemol (ES) was dissolved in methanol to prepare a 20 mg / mL solution; an appropriate volume of serum albumin (HSA) solution was placed in a sample bottle and stirred on a magnetic stirrer at 800 rpm, and ES solution was slowly added to the HSA solution while stirring, so that the final ratio of each component in the solution was HSA:ES=5:1, and stirred overnight in the dark; free molecules were removed by centrifugation at 3000 rpm for 5 min, and the supernatant was dialyzed in PBS for 24 h (MWCO=14 kDa) to obtain ES@HSA albumin-bound drug; C18-targeted Cyt c nucleic acid aptamer was added thereto (specific sequence reference Shamsipur, Mojtaba, et al. "Impedimetric monitoring of apoptosis using cytochrome-aptamerbioconjugated silver nanocluster." Biosensors & Bioelectronics (2016): 195-202 Experimental Materials Anti-Cyt c aptamers C1 sequence) until the final concentration of the aptamer is 1 μM, and then incubated on an Eppendorp Thermomixer at 37°C, 300 rpm for 4 h to finally obtain ES@HSA-Apt, which can be temporarily stored at 4°C for later use.
[0071] 3. Preparation of ES@HSA / CAT-Apt
[0072] First, elisemol (ES) was dissolved in methanol to prepare a 20 mg / mL solution; 36 g of serum albumin (HSA) and 4 g of catalase (CAT) were weighed and dissolved in deionized water and placed on a magnetic stirrer and stirred at 800 rpm. ES solution was slowly added to the above solution while stirring, so that the final ratio of each component in the solution was HSA:ES:CAT=45:9:5, and stirred overnight in the dark; free molecules were removed by centrifugation at 3000 rpm for 5 min, and the supernatant was dialyzed in PBS for 24 h (MWCO=14 kDa) to obtain ES@HSA / CAT albumin-bound drug; C18-targeted Cyt c nucleic acid aptamer was added thereto until the final concentration of the aptamer was 1 μM, and then incubated on an Eppendorp Thermomixer at 37°C, 300 rpm for 4 h to finally obtain ES@HSA / CAT-Apt, and the product could be temporarily stored at 4°C for later use.
[0073] 2. Property detection of albumin drug spherical nucleic acid:
[0074] 1. Structural characterization of albumin-targeted spherical nucleic acid drugs
[0075] The targeted albumin spherical nucleic acid drugs loaded with different hydrophobic drugs were characterized by transmission electron microscopy to observe the morphology and distribution of their nanostructures. At the same time, the aqueous solution of the albumin spherical nucleic acid drug was diluted ten times, and the particle size of the drug was detected in a nanoparticle size analyzer and compared with the albumin drug without modified nucleic acid aptamer.
[0076] The experimental results are as attached Figure 2 , transmission electron microscopy results show that our synthetic strategy has broad versatility and can be self-assembled with a variety of hydrophobic drugs to form spherical structures under hydrophobic effects. Figure 2 The curve graph is the measurement result of the hydrated particle size of the corresponding albumin drug solution. It can be seen that after the surface is modified with nucleic acid aptamers, the particle size is slightly increased compared with the albumin drug without nucleic acid aptamer modification.
[0077] 2. Structural characterization of albumin drug spherical nucleic acid before and after freeze-drying and reconstitution
[0078] Freeze the prepared albumin drug spherical nucleic acid at -20℃ for 2 hours and take it out after solidification. Seal the solidified albumin drug with sealing film or plastic wrap, making sure to leave air holes, and place it in a freeze dryer for 48 hours until the sample is a powder or flake solid. After freeze drying, it can be reconstituted with PBS or ddH2O, and the reconstituted albumin drug solution can be stored at 4℃ for later use.
[0079] To prove the stability of non-covalent modification between nucleic acid aptamers and albumin drugs before and after freeze-drying, samples of Apt, PTX@HSA-Apt before freeze-drying-redissolution, and PTX@HSA-Apt after freeze-drying-redissolution were added to the wells of 15% SDS-PAGE gel in turn, and electrophoresed at 120V for 45 minutes in 1×TBE buffer. After the electrophoresis, the gel was taken out and placed on a shaker, and stained with an appropriate amount of 1×GelRed nucleic acid dye for 30 minutes, and then imaged and observed after decolorization with deionized water. Next, the gel was boiled in deionized water for 3 minutes, and then stained with Coomassie Brilliant Blue Rapid Staining Solution for 10 minutes. After decolorization with deionized water, the position and color development of the blue band were observed, and the results were photographed and saved.
[0080] The experimental results are as attached Figure 3 (a)-(d), Figure c and Figure d are photos of the large-scale preparation of 100 mL PTX@HSA-Apt before and after lyophilization; the nanoparticle size and band color after lyophilization and reconstitution are shown in the attached Figure 3 (a), (b), the results show that the albumin spherical nucleic acid structure has not been degraded and the stability of the non-covalent hydrophobic connection is good.
[0081] 3. Photothermal stability of IR / Res@HSA-Apt
[0082] The photothermal conversion performance of IR / Res@HSA-Apt was studied using a thermal imaging system.
[0083] IR / Res@HSA-Apt nanoparticle dispersions with different concentrations were heated at 1 W / cm 2 The power density was exposed to 1064nm wavelength laser (with high penetration and high resolution) for 6 minutes, and deionized water treated in the same way was used as a blank control. The temperature was measured with a digital temperature detector at intervals of 30 seconds to observe the heating effect of IR / Res@HSA-Apt. The results are shown in the attached Figure 4 As shown in (a), it can be seen that the concentration of IR / Res@HSA-Apt has a significant effect on the sensitivity of the heating curve. As the concentration of IR1061 in IR / Res@HSA-Apt increases, the heating rate of the solution also accelerates.
[0084] In addition, the IR / Res@HSA-Apt was repeatedly exposed to laser irradiation, and the temperature rise and fall of the material were recorded every 30 seconds until the material temperature returned to the initial temperature before the next laser irradiation was started to observe the photothermal conversion ability of IR / Res@HSA-Apt. The experimental results are shown in the attached figure. Figure 4 As shown in (b), it can be seen that IR / Res@HSA-Apt has stable photothermal conversion performance.
[0085] 4. Inhibition of heat shock proteins by IR / Res@HSA-Apt
[0086] First, 4T1 cells were inoculated in a six-well plate and incubated for 12 hours. After the cells adhered to the wall, 20 mg / mL of IR@HSA-Apt and IR / Res@HSA-Apt (with HSA feed ratio as the measurement standard) were added and incubated for 2 hours. Subsequently, the cells treated with IR@HSA-Apt and IR / Res@HSA-Apt were exposed to 1064nm laser irradiation for 30 minutes. In addition, wells that were not exposed to light were set up after PBS and IR / Res@HSA-Apt treatment for 2 hours to verify the inhibitory effect of IR / Res@HSA-Apt on intracellular heat shock proteins under normal culture conditions. Next, 120 μL of complete lysis buffer was added to each well to extract the cell proteins of each group. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal reference. Western blotting experiments were used to detect the expression of HSP70 and HSP90 in 4T1 cells under different treatments. The expression of HSP70 and HSP90 was downregulated by the addition of Res-targeted albumin drugs.
[0087] 3. Targeting and therapeutic effects of albumin drug spherical nucleic acid:
[0088] 1. Aptamer-mediated albumin drug targeting ability in vitro
[0089] (1) In vitro tumor targeting ability of IR / Res@HSA-Apt
[0090] Flow cytometry was used to further verify the targeting ability of the aptamer. 4 / well, washed with binding buffer after digestion, and added with random sequence (random DNA, rDNA) modified IR / Res@HSA-rDNA-FITC and aptamer modified IR / Res@HSA-Apt-FITC, incubated in the dark at 4°C for 2 hours, centrifuged at 600g three times to remove unbound aptamers. Then the cells were collected in the FITC channel and analyzed by flow cytometry.
[0091] The experimental results are shown in the attached Figure 5 , IR / Res@HSA-Apt linked to SYL3C aptamer can clearly bind to the surface of 4T1 cells, showing high targeting ability. However, after modifying the random sequence, it cannot help albumin-binding drugs recognize the markers of 4T1 cells.
[0092] (2) Lysosomal escape ability of ES@HSA / CAT-Apt
[0093] First, PANC02 cells (mouse pancreatic cancer cells) were seeded in 24-well plates (3×10 4 Cells) were cultured overnight at 37°C in a cell culture incubator containing 5% CO2. Then, ES@HSA-Apt-cy5 modified with mitochondrial targeting aptamer Cyt c-Apt was added and incubated in the dark at 37°C for 1, 4, and 8 hours, respectively, and then gently washed 3 times with PBS to remove excess drugs. Then, the cells were incubated with green fluorescent labeled lysosomal probe working solution at 37°C for 15 minutes, and the Lyso-TrackerGreen staining working solution was removed. After washing with PBS 3 times, all cells were co-localized using a Leica SP8 laser scanning confocal microscope to verify their co-localization with lysosomes at different times.
[0094] Results refer to the attached Figure 6 : ES@HSA / CAT-Apt enters the cytoplasm after 1 hour, co-localizes with the lysosome after 4 hours, and escapes from the lysosome and relocalizes in the cytoplasm after 8 hours. The Gray value in the lower row shows the co-localization of the two fluorescent signals. The higher the overlap on the overlapping line we drew, the stronger the co-localization, showing excellent lysosomal escape ability. Effective lysosomal escape can reduce the probability of drug degradation and clearance by lysosomes, allowing it to accumulate more in the mitochondrial site to exert its effect.
[0095] (3) In vitro mitochondrial targeting ability of ES@HSA / CAT-Apt
[0096] First, PANC02 cells (mouse pancreatic cancer cells) were seeded in 24-well plates (3×10 4 Cells) were cultured overnight at 37°C in a cell culture incubator containing 5% CO2. Then, ES@HSA-Apt-cy5 modified with mitochondrial targeting aptamer Cyt c-Apt and ES@HSA-rDNA-cy5 modified with any sequence were added, incubated in the dark at 37°C for 4 hours, and then gently washed 3 times with PBS to remove excess drugs. Then, the cells were incubated with green fluorescent labeled mitochondrial probe working solution at 37°C for 15 minutes, and the Mito-Tracker Green staining working solution was removed. After washing with PBS 3 times, all cells were co-localized and imaged using a Leica SP8 laser scanning confocal microscope to verify its targeting ability.
[0097] Results refer to the attached Figure 7: Compared with the control group and the random sequence modification group, the fluorescence signal of ES@HSA / CAT-Apt co-localized with the mitochondrial probe (mito-tracker) more obviously. The Gray value in the lower row shows the co-localization of the two fluorescence signals. The higher the overlap on the overlapping line we drew, the stronger the co-localization, showing excellent targeting performance.
[0098] 2. In vitro cytotoxicity assay of albumin-drug spherical nucleic acids
[0099] (1) Cytotoxicity assay of IR / Res@HSA-Apt
[0100] 4T1 cells were seeded in 96-well plates (1×10 4 After incubation with cells for 2 hours, Res@HSA, IR@HSA, IR / Res@HSA and IR / Res@HSA-Apt at different concentrations were irradiated with 1064nm laser at a power density of 1W / cm2 for 5 minutes. PBS and wells without light treatment after incubation with different concentrations of IR / Res@HSA-Apt were set as controls. The cells were then placed in a cell culture incubator for another 6-8 hours, and the cell survival rate was detected by the standard CCK-8 method.
[0101] The cell apoptosis was determined using the Annexin V-FITC apoptosis detection kit (Biyuntian, C1062M). 4T1 cells were seeded in 24-well plates (5×10 4 Cells / well) were incubated for 24 hours. After 2 hours of administration, PBS was used to wash and the culture medium was replaced to remove non-targeted drugs. Each group of materials received two treatment methods, one with light or without light. After incubation for 6-8 hours, all cells were collected, centrifuged at 600g for 5 minutes, the supernatant was discarded, and 195μl Annexin V-FITC binding solution was added to resuspend the cells. 5μl Annexin V-FITC and 10μl propidium iodide staining solution were added to each group of cells and gently mixed. Incubate at 25℃ in the dark for 30 minutes, wash to remove unbound fluorescent dye, and use flow cytometry to detect cell apoptosis in each group.
[0102] The experimental results are attached. Figure 8 (a): The results of cell proliferation and cytotoxicity tests showed that when the drug concentration reached 20 mg / mL, IR / Res@HSA and IR / Res@HSA-Apt could significantly reduce the number of viable cancer cells under light conditions, and the therapeutic effect was significant; we used the Annexin V / PI method ( Figure 8 (b) Further analysis revealed that IR / Res@HSA-Apt induced a significant apoptosis effect under light conditions.
[0103] (2) Cytotoxicity assay of ES@HSA / CAT-Apt
[0104] PANC02 cells were seeded in 96-well plates (1×10 4 Cells were incubated with PBS and different concentrations of ES, ES@HSA, ES@HSA / CAT and ES@HSA / CAT-Apt for 24 hours, and the cell viability was detected by standard CCK-8 method.
[0105] The experimental results are as attached Figure 8 As shown in (c), compared with ES and ES@HSA, ES@HSA / CAT and ES@HSA / CAT-Apt both showed significant tumor killing effects. Among them, compared with ES@HSA / CAT without aptamer modification, the albumin drug ES@HSA / CAT-Apt modified with aptamers on the surface showed the strongest killing effect, indicating that the targeted recognition of aptamers in ES@HSA / CAT-Apt played an important role in tumor copper death and could significantly improve the therapeutic effect of copper death.
[0106] 3. Detection of the in vivo targeting ability of albumin drugs mediated by nucleic acid aptamers
[0107] We further studied the targeting and retention of IR@HSA-Apt at the tumor site by in vivo experiments using a mouse intravenous injection model. We injected IR@HSA and IR@HSA-Apt into the tail vein of 4T1 tumor-bearing mice, and imaged the tumor site with a near-infrared two-zone imager at 1, 2, 4, 8, 12, 24, and 36 hours to observe the fluorescence accumulation. After 36 hours, tumor tissues and various organs were taken for in vitro imaging.
[0108] The experimental results are shown in the attached Fig. 9 a, b, The results showed that compared with the IR@HSA group, the IR@HSA-Apt group had a more accurate targeting area ( Fig. 9 a) has an excellent aggregation effect, and the fluorescent area does not diffuse in the peripheral area. At the same time, its fluorescent signal retention effect persists and even continues to increase over time, without the dissipation shown in the control group.
[0109] This experiment shows that compared with the traditional albumin drug control group, the spherical nucleic acid drug formed by nucleic acid aptamer-modified albumin drug can significantly enhance the targeted accumulation and retention of albumin-binding drugs at the lesion site, which greatly exceeds expectations in terms of drug targeting and retention capabilities, making the drug of the present invention have targeting and stability that significantly surpass traditional drugs.
[0110] 4. In vivo photothermal effect experiment of IR / Res@HSA-Apt
[0111] In order to determine the local temperature rise of the tumor caused by photothermal therapy during the high accumulation of IR@HSA-Apt, we used a thermal imager to monitor the temperature changes in the tumor site of 4T1 tumor-bearing mice.
[0112] When the tumor is about 50 mm 3 200 μL PBS, IR@HSA and IR@HSA-Apt were injected intravenously into 4T1 tumor-bearing mice. 24 hours later, the cells were heated at 1 W / cm 2 The 1064 nm laser was used to irradiate the tumor site of mice for 20 minutes, and the temperature of the tumor site was recorded at 30 second intervals.
[0113] The experimental results refer to the attached Fig.10 For mice injected with IR@HSA or IR@HSA-Apt, the surface temperature of the tumor rapidly increased to about 43°C and remained stable; while for mice injected with PBS under the same laser, the tumor temperature remained almost unchanged below 35°C. This indicates that IR@HSA-Apt still has good photothermal conversion performance in vivo, and the modification of nucleic acid aptamers has no negative impact on the successful conversion of photothermal effect while providing strong targeting and stability.
[0114] 5. Mild photothermal therapy of tumors based on IR / Res@HSA-Apt
[0115] The tumor-bearing mouse model was established by subcutaneously injecting mouse breast cancer cells 4T1 (1×106 cells / mouse) into 6-8 week-old female Balb / c mice. After 3 days, the tumor size of the mice reached about 50 mm. 3 The mice were randomly divided into 5 groups for treatment: PBS group, Res@HSA+1064nm light group, IR / Res@HSA+1064nm light group, IR / Res@HSA-Apt group and IR / Res@HSA-Apt+1064nm light group, with at least 5 mice in each group. During the treatment, 200μL 20mg / mL of the corresponding drug was injected through the tail vein on the third day after tumor modeling. 24 hours after administration, the tumor site of each mouse that needed light treatment was illuminated with 1064nm laser at 1W / cm 2 The power density was irradiated for 10 minutes, and the tumor size of mice was monitored every other day for 16 consecutive days (V = length × width 2 / 2) and body weight changes. The mice were euthanized on day 16, and the main organs and tumors were collected from the sacrificed mice for hematoxylin-eosin (H&E) staining analysis and various immunofluorescence analyses.
[0116] The experimental results refer to the attached Fig.11ac: Compared with the PBS group, Res@HSAL+ and IR / Res@HSA-Apt did not significantly inhibit tumor growth due to the lack of photothermal conversion; and due to the low accumulation level and short retention time of the albumin drug of the unmodified nucleic acid aptamer in the tumor tissue, IR / Res@HSA L+ could only partially delay tumor growth. In contrast, the spherical nucleic acid drug of the present invention (IR / Res@HSA-Apt L+) showed obvious tumor growth inhibition under light conditions due to its simultaneous tumor targeting ability and mild photothermal conversion ability, and its therapeutic effect was significantly better than any other treatment group ( Fig.11 a). At the same time, the body weight of mice in each group remained at a stable level during the treatment period, and no obvious biological toxicity was shown ( Fig.11 b).
[0117] In addition, we investigated the regulation of heat shock proteins of tumor cells by Res in mild photothermal therapy through in vivo experiments. We divided tumor-bearing mice into four groups: PBS, IR@HSA-Apt L+, IR / Res@HSA-Apt, and IR / Res@HSA-Apt L+, and the treatment methods were as described above. Tumors from each group were taken for immunofluorescence analysis. Compared with PBS, HSP70 and HSP90 in tumor tissues of IR@HSA-Apt L+ showed a significant increase trend under the action of photothermal conversion. After injection of IR / Res@HSA-Apt, the contents of HSP70 and HSP90 were significantly decreased compared with the IR@HSA-Apt L+ or PBS groups after illumination or no illumination treatment, which proved that Res inhibited heat shock proteins in tumor cells in vivo and effectively promoted the photothermal therapy process in tumor cells.
[0118] 6. Tumor copper death therapy based on ES@HSA / CAT-Apt
[0119] Mouse pancreatic cancer cells Panc02 (1×10 6 The tumor-bearing mouse model was constructed with 10 cells / mouse. After 18 days, the tumor of the mouse reached about 90 mm. 3 The mice were randomly divided into 6 groups for treatment: PBS group, ES group, ES@HSA group, ES@HSA-Apt group, ES@HSA / CAT group and ES@HSA / CAT-Apt group, with at least 5 mice in each group. During the treatment, 100 μL of 20 mg / mL of the corresponding drug was injected through the tail vein on the 18th, 21st and 24th day after tumor modeling, and the tumor size of the mice (V = length × width) was monitored every other day. 2 / 2) and body weight changes. The mice were euthanized on day 40, and the main organs and tumors were collected from the sacrificed mice for hematoxylin-eosin (H&E) staining analysis.
[0120] The experimental results refer to the attached Fig.12 ad, compared with the PBS group, the ES group, ES@HSA group, and ES@HSA-Apt group could only partially delay tumor growth. Since catalase (CAT) was added to the ES@HSA / CAT group to improve the hypoxic environment of the tumor, it could effectively enhance the copper death process that depends on mitochondrial respiration, showing a significant tumor growth inhibitory effect. In addition, the ES@HSA / CAT-Apt group added aptamers targeting mitochondria, which could make the drug more concentrated in the mitochondria where copper death occurs, showing a better tumor growth inhibitory effect than other groups ( Fig.12 a / c / d). At the same time, the body weight of mice in each group remained at a stable level during the treatment period, and no obvious biological toxicity was shown ( Fig.12 b).
[0121] Based on the above experimental results, the present invention introduces octadecyl as a hydrophobic structure into the 5' end of the nucleic acid aptamer, utilizes the naturally superior hydrophobic property of albumin to bind multiple nucleic acid aptamers at one time in vitro, and constructs a targeted albumin spherical nucleic acid drug, thereby being able to specifically deliver various hydrophobic drugs to tumors or other lesion tissues, effectively solving the problems that traditional albumin drugs cannot solve, such as poor targeting enrichment and strong systemic side effects.
[0122] In order to demonstrate in detail the excellent specific recognition and therapeutic effects of the albumin-targeted spherical nucleic acid drug of the present invention, the present invention verified the in vitro and in vivo performances of IR / Res@HSA-Apt used in tumor photothermal therapy and ES@HSA / CAT-Apt used in copper death treatment.
[0123] The drug IR / Res@HSA-Apt of the present invention can accurately deliver resveratrol and IR1061 to tumor tissues instead of adjacent cancer sites. It has precise drug targeting and good aggregation effect. The drug is not easy to diffuse and degrade over time. Compared with general albumin drugs, the drug's stability, aggregation density and retention time are all beyond expectations. In the tumor tissue in vivo, due to the excellent targeting and stability of the drug IR / Res@HSA-Apt, the two drugs IR1061 and Res can efficiently cooperate at the tumor site: using the excellent tissue penetration ability of the near-infrared zone II laser, IR1061 can achieve photothermal conversion at the tumor site under 1064nm laser irradiation, and Res-induced downregulation of HSP70 and HSP90 can overcome the thermal resistance of tumor cells, triggering high levels of tumor apoptosis at relatively low temperatures or PTT (43°C), and showing tumor-targeted therapeutic effects that significantly exceed other drugs in in vivo and in vitro experiments.
[0124] At the same time, we applied ES@HSA / CAT-Apt to the copper death treatment of pancreatic cancer. The enhanced permeability and retention effect (ERP) of solid tumors can achieve passive targeting of drugs, enriching ES@HSA / CAT-Apt at the tumor site. After the drug enters the tumor cell through endocytosis, the copper ion carrier ES is actively targeted to the site of copper death - mitochondria using mitochondrial targeting nucleic acid aptamers. In vitro, we studied that the drug ES@HSA / CAT-Apt of the present invention can efficiently achieve lysosomal escape (i.e., it will not be engulfed and degraded by intracellular lysosomes), and effectively target mitochondria to induce copper death in tumor cells. In in vivo experiments, we verified that the drug ES@HSA / CAT-Apt of the present invention can significantly and effectively induce tumor cell death in a mouse subcutaneous pancreatic cancer model.
[0125] It is worth mentioning that compared with existing commercial albumin-bound drugs (such as Abraxane), the targeted albumin spherical nucleic acid drug of the present invention can non-covalently link albumin with multivalent nucleic acid aptamers through a one-step method on the basis of the existing preparation method, thereby realizing the efficient transformation of traditional albumin drugs into albumin targeted drugs. At the same time, in addition to the above-mentioned significant in vivo targeting and stability, we have also proved that the drug of the present invention can continue to maintain a stable HSA-Apt composite structure after freeze-drying and re-dissolution. This excellent property is conducive to the production and storage of drugs, making the large-scale industrial production of the albumin spherical nucleic acid drug of the present invention possible, and it is expected to be directly applied to current clinical trials and commercial production.
[0126] Although the technical solutions of the present invention have been described and listed in detail, it should be understood that it is obvious to those skilled in the art to make modifications to the above-mentioned embodiments or adopt equivalent alternatives. These modifications or improvements made without departing from the spirit of the present invention are within the scope of protection claimed by the present invention.
Claims
1. A targeted albumin spherical nucleic acid drug, characterized in that: The albumin contains hydrophobic molecules, and at the same time, albumin (HSA) with multiple hydrophobic domains on the surface and multiple nucleic acid aptamer sequences (Apt) with hydrophobic groups at the 5' end are non-covalently modified and bound to each other through hydrophobic interactions to form a spherical nucleic acid structure. The nucleic acid aptamer has specific targeting.
2. A targeted albumin spherical nucleic acid drug according to claim 1, characterized in that: The hydrophobic molecules include one or more of paclitaxel (PTX), elisimol (ES), Ce6, IR1061 and resveratrol (Res).
3. A targeted albumin spherical nucleic acid drug according to claim 2, characterized in that: The nucleic acid aptamer sequence can specifically target tumor cells, and the hydrophobic molecules include IR1061 and resveratrol (Res) to form IR / Res@HSA-Apt albumin spherical nucleic acid drugs.
4. A targeted albumin spherical nucleic acid drug according to claim 3, characterized in that: The nucleic acid aptamer is SYL3C, which can specifically target the epithelial cell adhesion molecule EpCAM.
5. A targeted albumin spherical nucleic acid drug according to claim 2, characterized in that: The nucleic acid aptamer sequence specifically targets mitochondria, and the hydrophobic drug is elisemol (ES), so as to form ES@HSA-Apt albumin spherical nucleic acid drug.
6. A targeted albumin spherical nucleic acid drug according to claim 5, characterized in that: The nucleic acid aptamer sequence specifically targets cytochrome c molecules (Cyt c) on the surface of mitochondria.
7. The targeted albumin spherical nucleic acid drug according to claim 5, characterized in that: Catalase (CAT) was added to the ES@HSA-Apt conjugate to form ES@HSA / CAT-Apt albumin spherical nucleic acid drug.
8. The targeted albumin spherical nucleic acid drug according to claim 1, characterized in that: The hydrophobic group at the 5' end of the nucleic acid aptamer sequence is an octadecyl group.
9. A method for preparing a targeted albumin spherical nucleic acid drug: Step 1: Dissolve the hydrophobic drug; Step 2: Take an appropriate volume of albumin solution, slowly add the hydrophobic drug solution to the albumin solution in a predetermined ratio while stirring, and stir for a certain period of time in the dark; Step 3: Centrifuge after stirring to remove free molecules; Step 4: After centrifugation, the supernatant is dialyzed to obtain the albumin-bound drug (drug@HSA); Step 5: Add the nucleic acid aptamer sequence with a hydrophobic group at 5', incubate with constant temperature stirring, and obtain a targeted albumin spherical nucleic acid drug (drug @HSA-Apt).
10. A method for using a targeted albumin spherical nucleic acid drug: using the targeted albumin spherical nucleic acid drug according to claims 1 to 8 for the preparation of drugs related to tumor targeted therapy.
